Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending September 5, 2008. The report details a specific corporate action regarding the repurchase and cancellation of the company's ordinary shares, executed under authority granted by shareholders at the Annual General Meeting on May 21, 2008.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to the share buyback transaction:
- Shares Purchased: 1,100,000 Ordinary shares of 25 pence each.
- Purchase Price: 1,278.49 pence per share.
- Treasury Shares Held: 474,194,158 shares (representing 9.07% of total voting rights).
- Shares in Issue: 5,230,733,855 shares (excluding Treasury shares).
Material Changes
The material change reported is the reduction of the company's share capital through the cancellation of 1,100,000 shares purchased on September 5, 2008. Consequently, the total number of shares in issue was adjusted to 5,230,733,855, while the Treasury holding increased to 474,194,158 shares.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, outlook, or discussion of risks and contingencies. It is a statutory notification of a share transaction in conformity with the Financial Services Authority's Disclosure and Transparency Rules.
Key Facts for Investor Verification
- Verify the total cost of the buyback transaction (1,100,000 shares at 1,278.49 pence).
- Confirm the updated share count for voting rights calculations (5,230,733,855 shares in issue).
- Note that the Treasury share holding now represents 9.07% of total voting rights.
- Confirm that the purchased shares were cancelled rather than held for future reissue.